These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1467 related items for PubMed ID: 26246473

  • 1. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
    Ma L, Wang X, Jia T, Wei W, Chua MS, So S.
    Oncotarget; 2015 Sep 22; 6(28):25390-401. PubMed ID: 26246473
    [Abstract] [Full Text] [Related]

  • 2. Evidence for tankyrases as antineoplastic targets in lung cancer.
    Busch AM, Johnson KC, Stan RV, Sanglikar A, Ahmed Y, Dmitrovsky E, Freemantle SJ.
    BMC Cancer; 2013 Apr 28; 13():211. PubMed ID: 23621985
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of AXIN1 and AXIN2 as targets of tankyrase inhibition in hepatocellular carcinoma cell lines.
    Wang W, Liu P, Lavrijsen M, Li S, Zhang R, Li S, van de Geer WS, van de Werken HJG, Peppelenbosch MP, Smits R.
    Sci Rep; 2021 Apr 02; 11(1):7470. PubMed ID: 33811251
    [Abstract] [Full Text] [Related]

  • 4. The Anti-Tumor Activity of Succinyl Macrolactin A Is Mediated through the β-Catenin Destruction Complex via the Suppression of Tankyrase and PI3K/Akt.
    Regmi SC, Park SY, Kim SJ, Banskota S, Shah S, Kim DH, Kim JA.
    PLoS One; 2015 Apr 02; 10(11):e0141753. PubMed ID: 26544726
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
    Lin HH, Feng WC, Lu LC, Shao YY, Hsu CH, Cheng AL.
    Cancer Lett; 2016 Oct 10; 381(1):58-66. PubMed ID: 27431312
    [Abstract] [Full Text] [Related]

  • 6. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
    Lau T, Chan E, Callow M, Waaler J, Boggs J, Blake RA, Magnuson S, Sambrone A, Schutten M, Firestein R, Machon O, Korinek V, Choo E, Diaz D, Merchant M, Polakis P, Holsworth DD, Krauss S, Costa M.
    Cancer Res; 2013 May 15; 73(10):3132-44. PubMed ID: 23539443
    [Abstract] [Full Text] [Related]

  • 7. Tankyrase Inhibitors Stimulate the Ability of Tankyrases to Bind Axin and Drive Assembly of β-Catenin Degradation-Competent Axin Puncta.
    Martino-Echarri E, Brocardo MG, Mills KM, Henderson BR.
    PLoS One; 2016 May 15; 11(3):e0150484. PubMed ID: 26930278
    [Abstract] [Full Text] [Related]

  • 8. E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.
    McGonigle S, Chen Z, Wu J, Chang P, Kolber-Simonds D, Ackermann K, Twine NC, Shie JL, Miu JT, Huang KC, Moniz GA, Nomoto K.
    Oncotarget; 2015 Dec 01; 6(38):41307-23. PubMed ID: 26513298
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells.
    Bao R, Christova T, Song S, Angers S, Yan X, Attisano L.
    PLoS One; 2012 Dec 01; 7(11):e48670. PubMed ID: 23144924
    [Abstract] [Full Text] [Related]

  • 10. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.
    Waaler J, Machon O, Tumova L, Dinh H, Korinek V, Wilson SR, Paulsen JE, Pedersen NM, Eide TJ, Machonova O, Gradl D, Voronkov A, von Kries JP, Krauss S.
    Cancer Res; 2012 Jun 01; 72(11):2822-32. PubMed ID: 22440753
    [Abstract] [Full Text] [Related]

  • 11. Formation of Tankyrase Inhibitor-Induced Degradasomes Requires Proteasome Activity.
    Pedersen NM, Thorvaldsen TE, Schultz SW, Wenzel EM, Stenmark H.
    PLoS One; 2016 Jun 01; 11(8):e0160507. PubMed ID: 27482906
    [Abstract] [Full Text] [Related]

  • 12. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
    Ni CX, Qi Y, Zhang J, Liu Y, Xu WH, Xu J, Hu HG, Wu QY, Wang Y, Zhang JP.
    Oncotarget; 2016 Nov 29; 7(48):79544-79556. PubMed ID: 27783993
    [Abstract] [Full Text] [Related]

  • 13. The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.
    Okada-Iwasaki R, Takahashi Y, Watanabe Y, Ishida H, Saito J, Nakai R, Asai A.
    Mol Cancer Ther; 2016 Jul 29; 15(7):1525-34. PubMed ID: 27196752
    [Abstract] [Full Text] [Related]

  • 14. Bruceine D inhibits hepatocellular carcinoma growth by targeting β-catenin/jagged1 pathways.
    Cheng Z, Yuan X, Qu Y, Li X, Wu G, Li C, Zu X, Yang N, Ke X, Zhou J, Xie N, Xu X, Liu S, Shen Y, Li H, Zhang W.
    Cancer Lett; 2017 Sep 10; 403():195-205. PubMed ID: 28645563
    [Abstract] [Full Text] [Related]

  • 15. CUL4B activates Wnt/β-catenin signalling in hepatocellular carcinoma by repressing Wnt antagonists.
    Yuan J, Han B, Hu H, Qian Y, Liu Z, Wei Z, Liang X, Jiang B, Shao C, Gong Y.
    J Pathol; 2015 Apr 10; 235(5):784-95. PubMed ID: 25430888
    [Abstract] [Full Text] [Related]

  • 16. NLRC5 regulates cell proliferation, migration and invasion in hepatocellular carcinoma by targeting the Wnt/β-catenin signaling pathway.
    Peng YY, He YH, Chen C, Xu T, Li L, Ni MM, Meng XM, Huang C, Li J.
    Cancer Lett; 2016 Jun 28; 376(1):10-21. PubMed ID: 26975630
    [Abstract] [Full Text] [Related]

  • 17. SOX1 functions as a tumor suppressor by antagonizing the WNT/β-catenin signaling pathway in hepatocellular carcinoma.
    Tsao CM, Yan MD, Shih YL, Yu PN, Kuo CC, Lin WC, Li HJ, Lin YW.
    Hepatology; 2012 Dec 28; 56(6):2277-87. PubMed ID: 22767186
    [Abstract] [Full Text] [Related]

  • 18. Dichlorodiphenyltrichloroethane exposure induces the growth of hepatocellular carcinoma via Wnt/β-catenin pathway.
    Jin XT, Song L, Zhao JY, Li ZY, Zhao MR, Liu WP.
    Toxicol Lett; 2014 Feb 10; 225(1):158-66. PubMed ID: 24355586
    [Abstract] [Full Text] [Related]

  • 19. Down-regulated FSTL5 promotes cell proliferation and survival by affecting Wnt/β-catenin signaling in hepatocellular carcinoma.
    Zhang D, Ma X, Sun W, Cui P, Lu Z.
    Int J Clin Exp Pathol; 2015 Feb 10; 8(3):3386-94. PubMed ID: 26045876
    [Abstract] [Full Text] [Related]

  • 20. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
    Arqués O, Chicote I, Puig I, Tenbaum SP, Argilés G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG.
    Clin Cancer Res; 2016 Feb 01; 22(3):644-56. PubMed ID: 26224873
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 74.